<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Daru</journal-id><journal-id journal-id-type="publisher-id">DARU</journal-id><journal-title-group><journal-title>DARU : Journal of Faculty of Pharmacy, Tehran University of Medical Sciences</journal-title></journal-title-group><issn pub-type="ppub">1560-8115</issn><issn pub-type="epub">2008-2231</issn><publisher><publisher-name>Tehran University of Medical Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22615662</article-id><article-id pub-id-type="pmc">3232108</article-id><article-id pub-id-type="publisher-id">DARU-19-231</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>A comparison of the effects of reboxetine and placebo on reaction time in adults with Attention Deficit-Hyperactivity Disorder (ADHD)</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hashemian</surname><given-names>F</given-names></name><xref ref-type="aff" rid="AF0001">1</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Mohammadian</surname><given-names>S</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Riahi</surname><given-names>F</given-names></name><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Ghaeli</surname><given-names>P</given-names></name><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Ghodsi</surname><given-names>D</given-names></name><xref ref-type="aff" rid="AF0004">4</xref></contrib></contrib-group><aff id="AF0001"><label>1</label>Department of Clinical Pharmacy, Pharmaceutical Sciences BranchIslamic Azad University (IAU), Tehran</aff><aff id="AF0002"><label>2</label>Child and Adolescent Psychiatry Department, Jondi-Shapour University of Medical Sciences, Ahvaz</aff><aff id="AF0003"><label>3</label>Psychiatry and Psychology Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, Tehran</aff><aff id="AF0004"><label>4</label>Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran</aff><author-notes><corresp id="cor1">Correspondence: <email xlink:href="hashemian.f@iaups.ac.ir">hashemian.f@iaups.ac.ir</email></corresp></author-notes><pub-date pub-type="ppub"><year>2011</year></pub-date><volume>19</volume><issue>3</issue><fpage>231</fpage><lpage>235</lpage><history><date date-type="received"><day>06</day><month>9</month><year>2010</year></date><date date-type="rev-recd"><day>01</day><month>6</month><year>2011</year></date><date date-type="accepted"><day>12</day><month>6</month><year>2011</year></date></history><permissions><copyright-statement>&#x000a9; 2011 Tehran University of Medical Sciences</copyright-statement><copyright-year>2011</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.</license-p></license></permissions><abstract><sec id="st01"><title>Objective</title><p>
Some studies have demonstrated that Reaction Time (RT) is longer in patients with ADHD which in turn may be associated with educational and occupational impairment and increased driving risks. Any alteration on RT which is induced by the treatment in this population may have great consequences positively or negatively. This study was designed to examine the effects of reboxetine on RT in adults with Attention Deficit-Hyperactivity Disorder (ADHD).</p></sec><sec id="st02"><title>Methods</title><p>
A total of 30 adult patients with ADHD who did not suffer from any other major psychiatric disorder were eligible to participate in this double blind, placebo controlled study. Patients were randomly assigned to receive either reboxetine (4 mg/day for one week, then 8 mg/day) or placebo for 4 weeks. RT was assessed at baseline and after 4 weeks by validated software which collects and analyses the data for auditory and visual stimulants. Numbers of correct responses, omission and substitution errors for each stimulus were calculated.</p></sec><sec id="st03"><title>Results</title><p>
Regarding visual tasks and in comparison with baseline scores, the number of correct responses increased significantly and the number of omission errors decreased significantly after 4 weeks of treatment (P&#x0003c;0.05) in both groups. However, with regard to auditory tasks scores, no significant differences were found at the end of the study compared to the baseline in each of the two groups. Additionally, no significant differences were noted between the two groups when both visual and auditory tasks were considered.</p></sec><sec id="st04"><title>Conclusion</title><p>
Results of this study showed that reboxetine did not affect the RT of the patients when both visual and auditory tasks were assessed. Further studies with larger number of patients and for a longer period of time are required to confirm the result of this study.</p></sec></abstract><kwd-group><kwd>Visual and auditory tasks</kwd><kwd>Omission and Substitution errors.</kwd></kwd-group></article-meta></front><body><sec id="S0001"><title>INTRODUCTION</title><p>Attention Deficit Hyperactivity Disorder (ADHD) is a common psychiatric disorder that occurs in 3-7% of school aged children (<xref ref-type="bibr" rid="CIT0001">1</xref>&#x02013;<xref ref-type="bibr" rid="CIT0004">4</xref>). Many of these children do not receive any treatment and ADHD often persists into adulthood (<xref ref-type="bibr" rid="CIT0002">2</xref>, <xref ref-type="bibr" rid="CIT0005">5</xref>). The primary symptoms of ADHD involve different degrees of inattention, hyperactivity, impulsivity and distractibility (<xref ref-type="bibr" rid="CIT0002">2</xref>, <xref ref-type="bibr" rid="CIT0005">5</xref>)
(<xref ref-type="bibr" rid="CIT0006">6</xref>). Some symptoms of ADHD such as hyperactivity usually decrease with increasing age and maturation, however impulsivity and inattention often remain unchanged (<xref ref-type="bibr" rid="CIT0005">5</xref>).</p><p>Some studies have shown that children with ADHD tend to have longer Stop Signal Reaction Time (SSRT) in comparison with the healthy population (<xref ref-type="bibr" rid="CIT0006">6</xref>&#x02013;<xref ref-type="bibr" rid="CIT0009">9</xref>). Also, results of another study have noted that adults with a history of ADHD in childhood have longer Reaction Time (RT) (<xref ref-type="bibr" rid="CIT0010">10</xref>). Longer RT is associated with educational and occupational impairment and increases driving risks with fatal consequences (<xref ref-type="bibr" rid="CIT0005">5</xref>, <xref ref-type="bibr" rid="CIT0011">11</xref>). A study which was conducted in the UK with a sample size consistsed of 6424 participants and 21 years follow up, demonstrated that longer reaction times and poorer cognitive performance are related to an increased risk of mortality (<xref ref-type="bibr" rid="CIT0012">12</xref>). Reaction time is also important in sport fields (<xref ref-type="bibr" rid="CIT0013">13</xref>).</p><p>Pathophysiology of ADHD has been related to dysfunction of catecholaminergic neurotransmitters system (<xref ref-type="bibr" rid="CIT0001">1</xref>&#x02013;<xref ref-type="bibr" rid="CIT0003">3</xref>). As a result, stimulants and noradrenaline reuptake inhibitors have been considered as cornerstone of ADHD treatment (<xref ref-type="bibr" rid="CIT0001">1</xref>). Some studies support using methylphenidate (a stimulant) as a treatment for ADHD in most adults (<xref ref-type="bibr" rid="CIT0009">9</xref>, <xref ref-type="bibr" rid="CIT0014">14</xref>). Due to some side effects of stimulantsincluding changes in appetite and insomnia and due to their potential for abuse, the use of non-stimulant drugs may be preferred.</p><p>Atomoxetine is a selective inhibitor of noradrenaline transporter that has a minimal affinity for the serotonin and dopamine transporters (<xref ref-type="bibr" rid="CIT0002">2</xref>, <xref ref-type="bibr" rid="CIT0015">15</xref>)
(<xref ref-type="bibr" rid="CIT0016">16</xref>). It is the first medication approved for the treatment of ADHD in adults. It has a safe and efficient profile (<xref ref-type="bibr" rid="CIT0001">1</xref>) but is rather expensive (<xref ref-type="bibr" rid="CIT0017">17</xref>). Reboxetine which was first marketed as an antidepressant (<xref ref-type="bibr" rid="CIT0018">18</xref>), is a selective norepinephrine reuptake inhibitor and has a similar transporter/receptor profile as atomoxetine (<xref ref-type="bibr" rid="CIT0001">1</xref>) and has been recently studied in the treatment of ADHD (<xref ref-type="bibr" rid="CIT0019">19</xref>&#x02013;<xref ref-type="bibr" rid="CIT0021">21</xref>).</p><p>It has been reported that RT is longer in ADHD patients (<xref ref-type="bibr" rid="CIT0010">10</xref>) and the use of some other drugs including CNS-suppressants is also associated with increased RT which may lead to unwanted consequences like occupational and driving accidents in these patients (<xref ref-type="bibr" rid="CIT0022">22</xref>, <xref ref-type="bibr" rid="CIT0023">23</xref>). This double blind, randomized, placebo-controlled trial was designed to examine the effect of reboxetine on RT in adults with ADHD. Positive, negative or lacks of effect of the drug on RT in the study patients were matters of concern in this study.</p><sec><title/><sec><title>Patients and methods</title><p>Thirty adults 18 years old or older participated in this study. Since prevalence of ADHD in parents of children with ADHD is relatively high (<xref ref-type="bibr" rid="CIT0002">2</xref>), the subjects were selected among parents of children and adolescents with ADHD who had referred to adolescent psychiatry clinics of Imam Hossein and Roozbeh hospitals affiliated with Shaheed Beheshti University of Medical Sciences and Tehran University of Medical Sciences respectively. The diagnosis of ADHD was established by psychiatrists according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV&#x02013;TR) criteria (<xref ref-type="bibr" rid="CIT0024">24</xref>). The information about ADHD history in childhood was confirmed by one of the family member of each patient who remembered patient's manners and behaviors in childhood. In addition, each subject completed a self reported Conner's global index questionnaire; those who obtained the minimum score entered the study.</p><p>Demographic information and results of Hamilton anxiety and depression questionnaires were collected for each person at the beginning of the study. None of patients were taking psychotropic medications for at least 2 weeks before the initiation of the study. Exclusion criteria included presence of any other psychiatric disorders such as bipolar mood disorder and major depressive disorder, mental retardation, major medical illness such as hyperthyroidism, cardiovascular, kidney or pulmonary disease, pregnancy or lactation, drug or alcohol abuse and a history of seizure disorder. Patients who forgot taking at least 4 doses of their medications during the whole period of the study or missed at least 3 sequential doses as well as those with blood pressure above 140/90 mmHg were also excluded from the study. After verbal explanation of the study, each participant signed an informed consent.</p><p>Patients were randomly divided into two groups. One group received reboxetine and the other received placebo. All subjects received reboxetine or placebo for 4 weeks. Reboxetine was started at a dose of 4 mg once a day in the morning and after one week the drug dose was increased to 4 mg twice a day, one in the morning and one in the evening.</p><p>All participants were tested using software installed on a PC which was designed and validated by the authors under supervision of Islamic Azad University, Pharmaceutical Sciences Branch (IAUPS)-information technology division. It consisted of two tasks measuring RT to visual and auditory stimulants. Test procedures were presented either on a computer screen or speakers. Instructions were given orally and they were allowed to practice each test once to become familiar with the task. Visual task was included a series of colors (green, red, yellow and blue) presented in the computer screen for 1 second. The participants were asked to press the right button related to the color as quickly as possible after it appeared on the screen. In each test, RT for correct responses, number of correct responses, omission errors (lack of responses to target stimuli) and/or substitution errors (the number of incorrect response instead of the correct one) were calculated by the software.</p><p>With regard to the auditory task, the participants were asked to press the right button related to the played sound as quickly as it was heard. RTs for correct responses, number of correct responses, omission errors, and/or substitution errors were calculated again by the software.A total of 30 visual and 30 auditory targets were presented. Each participant performed the test at the beginning and at the end of the study. The same test was performed in both test sections for each patient.Statistical analyses were done by utilizing SPSS version 13 for windows; an alpha level less than of 0.05 was considered as significance of statistical association between variables. Paired sample t test was used to evaluate the effect of reboxetine and placebo on RT at each group at the beginning and end of the study. For comparison between the two groups, independent sample t test was used.</p></sec></sec></sec><sec id="S0004"><title>RESULTS</title><p>Eleven women and 7 men participated in the reboxetine group, in the control group there were 7 women and 5 men.</p><p>The means age of the patients in reboxetine and placebo groups were 31.3 and 32.1 years, respectively and the difference was not significant.</p><p>The number of correct responses, omission and substitution errors in response to visual and auditory stimuli in both groups at the baseline and the end of the study are presented in <xref ref-type="table" rid="T0001">table 1</xref>.
</p><table-wrap id="T0001" position="float"><label>Table 1</label><caption><p>Correct responses, omission and substitution errors at the baseline and at the end of the study. </p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" colspan="3" rowspan="1">Reboxetine (n=18)</th><th align="center" colspan="3" rowspan="1">Placebo (n=12)</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th colspan="3" rowspan="1"><hr/></th><th colspan="3" rowspan="1"><hr/></th></tr><tr><th align="left" rowspan="1" colspan="1">Group of the study</th><th align="center" rowspan="1" colspan="1">Baseline</th><th align="center" rowspan="1" colspan="1">End point</th><th align="center" rowspan="1" colspan="1">Pvalue</th><th align="center" rowspan="1" colspan="1">Baseline</th><th align="center" rowspan="1" colspan="1">End point</th><th align="center" rowspan="1" colspan="1">Pvalue</th></tr></thead><tbody><tr><td colspan="7" align="left" rowspan="1"><bold>Visual tasks</bold></td></tr><tr><td colspan="7" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Correct responses</td><td align="center" rowspan="1" colspan="1">7.5&#x000b1;5.24</td><td align="center" rowspan="1" colspan="1">12.61&#x000b1;6.73</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="TF0001">*</xref></td><td align="center" rowspan="1" colspan="1">11.08&#x000b1;8.28</td><td align="center" rowspan="1" colspan="1">16.17&#x000b1;9.57</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="TF0001">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Substitution errors</td><td align="center" rowspan="1" colspan="1">8.72&#x000b1;2.76</td><td align="center" rowspan="1" colspan="1">9.00&#x000b1;3.31</td><td align="center" rowspan="1" colspan="1">0.77</td><td align="center" rowspan="1" colspan="1">8.33&#x000b1; 4.14</td><td align="center" rowspan="1" colspan="1">6.17&#x000b1;4.34</td><td align="center" rowspan="1" colspan="1">0.126</td></tr><tr><td align="left" rowspan="1" colspan="1">Omission errors</td><td align="center" rowspan="1" colspan="1">13.78&#x000b1;4.85</td><td align="center" rowspan="1" colspan="1">8.39&#x000b1;4.02</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="TF0001">*</xref></td><td align="center" rowspan="1" colspan="1">10.58&#x000b1;7.14</td><td align="center" rowspan="1" colspan="1">7.67&#x000b1;6.44</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="TF0001">*</xref></td></tr><tr><td colspan="7" align="left" rowspan="1"><bold>Auditory tasks</bold></td></tr><tr><td colspan="7" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Correct responses</td><td align="center" rowspan="1" colspan="1">4.72&#x000b1;3.48</td><td align="center" rowspan="1" colspan="1">6.83&#x000b1;3.99</td><td align="center" rowspan="1" colspan="1">0.052</td><td align="center" rowspan="1" colspan="1">7.75&#x000b1;4.99</td><td align="center" rowspan="1" colspan="1">8.08&#x000b1;1.78</td><td align="center" rowspan="1" colspan="1">0.259</td></tr><tr><td align="left" rowspan="1" colspan="1">Substitution errors</td><td align="center" rowspan="1" colspan="1">12.06&#x000b1;4.17</td><td align="center" rowspan="1" colspan="1">12.11&#x000b1;4.85</td><td align="center" rowspan="1" colspan="1">0.968</td><td align="center" rowspan="1" colspan="1">12.5&#x000b1;5.50</td><td align="center" rowspan="1" colspan="1">13.75&#x000b1;3.17</td><td align="center" rowspan="1" colspan="1">0.575</td></tr><tr><td align="left" rowspan="1" colspan="1">Omission errors</td><td align="center" rowspan="1" colspan="1">13.22&#x000b1;5.14</td><td align="center" rowspan="1" colspan="1">11.11&#x000b1;5.48</td><td align="center" rowspan="1" colspan="1">0.172</td><td align="center" rowspan="1" colspan="1">9.75&#x000b1;6.21</td><td align="center" rowspan="1" colspan="1">8.17&#x000b1;4.00</td><td align="center" rowspan="1" colspan="1">0.196</td></tr></tbody></table><table-wrap-foot><fn id="TF0001"><label>*</label><p>: Significant differences at the end of the study in comparison with the baseline in each group (P&#x0003c;0.001)</p></fn></table-wrap-foot></table-wrap><table-wrap id="T0002" position="float"><label>Table 2</label><caption><p>Mean of reaction time (RT) in the reboxetine and placebo groups at the baseline and at the end of the study<xref ref-type="table-fn" rid="TF0002">&#x02020;</xref>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" colspan="3" rowspan="1">Reboxetine (n=18)</th><th align="center" colspan="3" rowspan="1">Placebo (n=12)</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th colspan="3" rowspan="1"><hr/></th><th colspan="3" rowspan="1"><hr/></th></tr><tr><th align="left" rowspan="1" colspan="1">Group of the study</th><th align="center" rowspan="1" colspan="1">Baseline</th><th align="center" rowspan="1" colspan="1">End point</th><th align="center" rowspan="1" colspan="1">P value</th><th align="center" rowspan="1" colspan="1">Baseline</th><th align="center" rowspan="1" colspan="1">End point</th><th align="center" rowspan="1" colspan="1">P value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Visual tasks</bold></td><td align="center" rowspan="1" colspan="1">0.617&#x000b1;0.159</td><td align="center" rowspan="1" colspan="1">0.646&#x000b1;0.075</td><td align="center" rowspan="1" colspan="1">0.426</td><td align="center" rowspan="1" colspan="1">0.596&#x000b1;0.083</td><td align="center" rowspan="1" colspan="1">0.632&#x000b1;0.105</td><td align="center" rowspan="1" colspan="1">0.199</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Auditory tasks</bold></td><td align="center" rowspan="1" colspan="1">0.583&#x000b1;0.201</td><td align="center" rowspan="1" colspan="1">0.573&#x000b1;0.178</td><td align="center" rowspan="1" colspan="1">0.827</td><td align="center" rowspan="1" colspan="1">0.668&#x000b1;0.124</td><td align="center" rowspan="1" colspan="1">0.610&#x000b1;0.105</td><td align="center" rowspan="1" colspan="1">0.586</td></tr></tbody></table><table-wrap-foot><fn id="TF0002"><label>&#x02020;</label><p>: The data are in mean&#x000b1;standard deviation ( in seconds).</p></fn></table-wrap-foot></table-wrap><p>In visual tasks the number of correct responses increased significantly and the number of omission errors decreased significantly (P&#x0003c;0.05) at the end of the study in comparison with the baseline in both groups. In auditory tasks there were no significant (NS) differences in both groups; independent sample t test showed NS differences between two groups in both visual and auditory tasks. However it was noted that there was a trend toward more substitution errors in the reboxetine group in comparison with the placebo group. (p=0.07)</p></sec><sec id="S0005"><title>DISCUSSION</title><p>Different therapeutic class of drugs such as stimulants, [e.g. methylphenidate (MPH)], Tricycle antidepressants (TCAs) and several non-stimulant drugs such as atomoxetine and reboxetine are being used to treat ADHD and have been shown to be effective in reducing the symptoms of ADHD (<xref ref-type="bibr" rid="CIT0001">1</xref>, <xref ref-type="bibr" rid="CIT0003">3</xref>, <xref ref-type="bibr" rid="CIT0025">25</xref>&#x02013;<xref ref-type="bibr" rid="CIT0028">28</xref>). Several studies have shown that methylphenidate and other stimulants improved SSRT in adults and children with ADHD (<xref ref-type="bibr" rid="CIT0006">6</xref>, <xref ref-type="bibr" rid="CIT0027">27</xref>&#x02013;<xref ref-type="bibr" rid="CIT0030">30</xref>), but they have some adverse effects such as decreased appetite, insomnia and potential for abuse (<xref ref-type="bibr" rid="CIT0002">2</xref>, <xref ref-type="bibr" rid="CIT0031">31</xref>).</p><p>TCAs such as desipramine, amitriptyline and imipramine that have been used for the treatment of ADHD, may increase RT (<xref ref-type="bibr" rid="CIT0022">22</xref>, <xref ref-type="bibr" rid="CIT0023">23</xref>). As a result, these drugs are associated with an increase risk of car accidents with fatal consequences (<xref ref-type="bibr" rid="CIT0023">23</xref>). A comparison of the effect of reboxetine and amitriptyline on cognitive function and psychomotor performance in healthy subjects, showed that reboxetine had little or no effect on the performance, however amitriptyline increased RT (<xref ref-type="bibr" rid="CIT0032">32</xref>). Similarly, the driving risks increased in subjects while taking TCAs (<xref ref-type="bibr" rid="CIT0023">23</xref>). Similar results have been reported in patients with major depressive disorder (<xref ref-type="bibr" rid="CIT0022">22</xref>).</p><p>Atomoxetine is a selective norepinephrine reuptake inhibitor with almost no abuse potential and some studies have shown that it can decrease SSRT in adults with ADHD (<xref ref-type="bibr" rid="CIT0033">33</xref>).</p><p>Theoretically, reboxetine may decrease RT similar to atomoxetine. At the end of present study, significant differences were observed in the number of correct responses and omission errors in comparison with the baseline values in both reboxetine and placebo groups. These findings were similar to those in previous studies (<xref ref-type="bibr" rid="CIT0001">1</xref>, <xref ref-type="bibr" rid="CIT0035">35</xref>). Ferguson et al, compared the effects of reboxetine, paroxetine and placebo in depressed patients and found that reboxetine improved cognitive functions in comparison with the baseline (<xref ref-type="bibr" rid="CIT0036">36</xref>).</p><p>Results of present study showed that there were no differences in the mean of RT of correct answers compared to the baseline values in both groups. Hindmarch examined the effect of reboxetine and amitriptyline on psychomotor or cognitive function in healthy males. Consistent with the results of this study, it was reported that reboxetine had little effect on psychomotor or cognitive function. On the other hand, amitriptyline, even at low doses, impaired CNS function (<xref ref-type="bibr" rid="CIT0037">37</xref>). Siepman et al compared the effects of reboxetine on cognitive and autonomic functions with those of placebo in healthy subjects and found that reboxetine did not affect choice reaction, memory and psychomotor coordination (<xref ref-type="bibr" rid="CIT0038">38</xref>).</p><p>Similar to the results of previous studies, the present trial showed that reboxetine did not have any effects on RT (<xref ref-type="bibr" rid="CIT0023">23</xref>, <xref ref-type="bibr" rid="CIT0032">32</xref>, <xref ref-type="bibr" rid="CIT0038">38</xref>). It is suggested that reboxetine may be used in the treatment of patients with ADHD without considering negative or positive effects on RT.</p><p>In this study, neither reboxetine nor placebo showed any significant effects on the RT. This study was a preliminary study with only 4 weeks duration and with a limited number of patients. Further studies with more patients and longer period of time are required to confirm the result of this study</p></sec></body><back><ack><title>ACKNOWLEDGMENT</title><p>We wish to thank Dr. Zahra Shahrivar and Dr. Mahdi Tehrani-Doost for recruitment assistance at Roozbeh hospital.</p></ack><ref-list><title>REFERENCES</title><ref id="CIT0001"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arabgol</surname><given-names>F</given-names></name><name><surname>Panaghi</surname><given-names>L</given-names></name><name><surname>Hebrani</surname><given-names>P.</given-names></name></person-group><article-title>Reboxetine versus methylphenidate in treatment of children and adolescents with attention deficit&#x02013;hyperactivity disorder</article-title><source>Eur child Adolesc Psychiatry</source><year>2009</year><volume>18</volume><fpage>53</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">18563471</pub-id></element-citation></ref><ref id="CIT0002"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banaschew ski</surname><given-names>T</given-names></name><name><surname>Roessner</surname><given-names>V</given-names></name><name><surname>Rothenberger</surname><given-names>A.</given-names></name></person-group><article-title>Non&#x02013;stimulant medications in the treatment of ADHD</article-title><source>Eur Child Adolesc Psychiatry</source><year>2004</year><volume>13</volume><fpage>102</fpage><lpage>116</lpage></element-citation></ref><ref id="CIT0003"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biederman</surname><given-names>J</given-names></name><name><surname>Heiligenstein</surname><given-names>JH</given-names></name><name><surname>Faries</surname><given-names>DE</given-names></name><name><surname>Galil</surname><given-names>N</given-names></name><name><surname>Dittmann</surname><given-names>R</given-names></name><name><surname>Emslie</surname><given-names>GJ</given-names></name><name><surname>Kratochvil</surname><given-names>CJ</given-names></name><name><surname>Laws</surname><given-names>HF</given-names></name><name><surname>Schuh</surname><given-names>KJ.</given-names></name></person-group><article-title>Efficacy of atomoxetine versus placebo in school&#x02013;age girls with Attention&#x02013;Deficit/Hyperactivity Disorder</article-title><source>Pediatrics</source><year>2002</year><volume>110</volume><fpage>75</fpage></element-citation></ref><ref id="CIT0004"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frank</surname><given-names>MJ</given-names></name><name><surname>Santamaria</surname><given-names>A</given-names></name><name><surname>Reilly</surname><given-names>Rco</given-names></name><name><surname>Willcutt</surname><given-names>E</given-names></name></person-group><article-title>Testing Computational models of dopamine and noradrenaline dysfunction in Attention Deficit/Hyperactivity Disorder</article-title><source>Neuropsychopharmacology</source><year>2007</year><volume>32</volume><fpage>1583</fpage><lpage>1599</lpage><pub-id pub-id-type="pmid">17164816</pub-id></element-citation></ref><ref id="CIT0005"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barry</surname><given-names>RJ</given-names></name><name><surname>Clarke</surname><given-names>AR</given-names></name><name><surname>Mccarthy</surname><given-names>R</given-names></name><name><surname>Selikowitz</surname><given-names>M</given-names></name><name><surname>Brown</surname><given-names>CR</given-names></name><name><surname>Heaven</surname><given-names>PC.</given-names></name></person-group><article-title>Event&#x02013;related potentials in adults with Attention-deficit/hyperactivity disorder: An investigation using an inter&#x02013;modal auditory/visual odd ball task</article-title><source>Int J Psychophysiol</source><year>2009</year><volume>71</volume><fpage>124</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">19022305</pub-id></element-citation></ref><ref id="CIT0006"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eagle</surname><given-names>DM</given-names></name><name><surname>Tofft</surname><given-names>MR.A</given-names></name><name><surname>Goodchild</surname><given-names>HL</given-names></name><name><surname>Robbins</surname><given-names>TW.</given-names></name></person-group><article-title>Differential effects of modafinil and methylphenidate on stop&#x02013;signal reaction time task performance in the rat, and interactions with the dopamine receptor antagonist Cis-Flupenthixol</article-title><source>J Psychopahrmacol</source><year>2007</year><volume>192</volume><fpage>193</fpage><lpage>206</lpage></element-citation></ref><ref id="CIT0007"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alderson</surname><given-names>RM</given-names></name><name><surname>Rapport</surname><given-names>MD</given-names></name><name><surname>Kofler</surname><given-names>MJ.</given-names></name></person-group><article-title>Attention-Deficit/Hyperactivity Disorder and Benavioral Inhibition: A Meta&#x02013;Analytic Review of the Stop-signal Paradigm</article-title><source>J Abnorm Child Psychol</source><year>2007</year><volume>35</volume><fpage>745</fpage><lpage>758</lpage><pub-id pub-id-type="pmid">17668315</pub-id></element-citation></ref><ref id="CIT0008"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andreou</surname><given-names>P</given-names></name><name><surname>Neale</surname><given-names>BM</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Christian</surname><given-names>H</given-names></name><name><surname>Gabriels</surname><given-names>I</given-names></name><name><surname>Meidad</surname><given-names>S</given-names></name><name><surname>Muller</surname><given-names>UC</given-names></name><name><surname>Uebel</surname><given-names>H</given-names></name><name><surname>Banaschewski</surname><given-names>T</given-names></name><name><surname>Manor</surname><given-names>I</given-names></name><name><surname>Oades</surname><given-names>R</given-names></name><name><surname>Roeyers</surname><given-names>H</given-names></name><name><surname>Rothenberger</surname><given-names>A</given-names></name><name><surname>Sham</surname><given-names>P</given-names></name><name><surname>Steinhausen</surname><given-names>HC</given-names></name><name><surname>Asherson</surname><given-names>P</given-names></name><name><surname>Kuntsi</surname><given-names>J.</given-names></name></person-group><article-title>Reaction Time performance in ADHD: improvement under fast&#x02013;incentive condition and familial effects</article-title><source>Psychol med</source><year>2007</year><volume>37</volume><fpage>1703</fpage><lpage>1715</lpage><pub-id pub-id-type="pmid">17537284</pub-id></element-citation></ref><ref id="CIT0009"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tucha</surname><given-names>O</given-names></name><name><surname>Mecklinger</surname><given-names>L</given-names></name><name><surname>Laufkotter</surname><given-names>R</given-names></name><name><surname>Klein</surname><given-names>HE</given-names></name><name><surname>Walitza</surname><given-names>S</given-names></name><name><surname>Lange</surname><given-names>KW.</given-names></name></person-group><article-title>Methylphenidate&#x02013;induced improvement of various measures of attention in adults with Attention Deficit/Hyperactivity Disorder</article-title><source>J Neural Transm</source><year>2006</year><volume>113</volume><fpage>1575</fpage><lpage>1592</lpage><pub-id pub-id-type="pmid">16897610</pub-id></element-citation></ref><ref id="CIT0010"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barkley</surname><given-names>RA</given-names></name><name><surname>Murphy</surname><given-names>KR</given-names></name><name><surname>Dupaul</surname><given-names>GJ</given-names></name><name><surname>Bush</surname><given-names>T.</given-names></name></person-group><article-title>Driving in young adults with attention deficit hyperactivity disorder: Knowledge, performance, adverse outcome, and the role of executive functioning</article-title><source>J Int Neuropsychol Soc</source><year>2002</year><volume>8</volume><fpage>655</fpage><lpage>672</lpage><pub-id pub-id-type="pmid">12164675</pub-id></element-citation></ref><ref id="CIT0011"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilens</surname><given-names>TE</given-names></name><name><surname>Adler</surname><given-names>LA</given-names></name><name><surname>Weiss</surname><given-names>MD</given-names></name><name><surname>Michelson</surname><given-names>D</given-names></name><name><surname>Ramsey</surname><given-names>JL</given-names></name><name><surname>Moore</surname><given-names>RJ</given-names></name><name><surname>Renard</surname><given-names>D</given-names></name><name><surname>Brady</surname><given-names>KT</given-names></name><name><surname>Trzepacz</surname><given-names>PT</given-names></name><name><surname>Schuh</surname><given-names>LM</given-names></name><name><surname>Ahrbecker</surname><given-names>LM</given-names></name><name><surname>Levine</surname><given-names>LR.</given-names></name></person-group><article-title>Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders</article-title><source>Drug Alcohol Depend</source><year>2008</year><volume>96</volume><fpage>145</fpage><lpage>154</lpage><pub-id pub-id-type="pmid">18403134</pub-id></element-citation></ref><ref id="CIT0012"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shipley</surname><given-names>BA</given-names></name><name><surname>Der</surname><given-names>G</given-names></name><name><surname>Tylor</surname><given-names>MD</given-names></name><name><surname>Deary</surname><given-names>IJ.</given-names></name></person-group><article-title>Cognition and mortality from the major causes of death: the Health and Lifestyle Survey</article-title><source>J Psychosomatic Res</source><year>2008</year><volume>65</volume><fpage>143</fpage><lpage>152</lpage></element-citation></ref><ref id="CIT0013"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dogan</surname><given-names>B.</given-names></name></person-group><article-title>Multiple-choice reaction and visual perception in female and male elite athletes</article-title><source>J Sports Med Phys Fitness</source><year>2009</year><volume>49</volume><fpage>91</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">19188901</pub-id></element-citation></ref><ref id="CIT0014"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schachar</surname><given-names>R</given-names></name><name><surname>Ickowicz</surname><given-names>A</given-names></name><name><surname>Crosbie</surname><given-names>J</given-names></name><name><surname>Donnelly</surname><given-names>GA</given-names></name><name><surname>Reiz</surname><given-names>JL</given-names></name><name><surname>Miceli</surname><given-names>PC</given-names></name><name><surname>Harsanyi</surname><given-names>Z</given-names></name><name><surname>Darke</surname><given-names>AC.</given-names></name></person-group><article-title>Cognitive and Behavioral Effects of Multilayer-Release Methyphenidate in the Treatment of Children with Attention-Deficit/Hyperactivity Disorder</article-title><source>J Child Adolesc Psychopharmacol</source><year>2008</year><volume>18</volume><fpage>11</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">18294084</pub-id></element-citation></ref><ref id="CIT0015"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>AJ</given-names></name><name><surname>Kurlan</surname><given-names>RM</given-names></name><name><surname>Gilber</surname><given-names>DL</given-names></name><name><surname>Coffey</surname><given-names>BJ</given-names></name><name><surname>Linder</surname><given-names>SL</given-names></name><name><surname>Lewis</surname><given-names>DW</given-names></name><name><surname>Winner</surname><given-names>PK</given-names></name><name><surname>Dunn</surname><given-names>DW</given-names></name><name><surname>Dure</surname><given-names>LS</given-names></name><name><surname>Sallee</surname><given-names>FR</given-names></name><name><surname>Milton</surname><given-names>DR</given-names></name><name><surname>Mintz</surname><given-names>MI</given-names></name><name><surname>Ricardi</surname><given-names>RK</given-names></name><name><surname>Erenberg</surname><given-names>G</given-names></name><name><surname>Layton</surname><given-names>LL</given-names></name><name><surname>Feldman</surname><given-names>PD</given-names></name><name><surname>Kelsey</surname><given-names>DK</given-names></name><name><surname>Spencer</surname><given-names>TJ.</given-names></name></person-group><article-title>Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorder</article-title><source>Neurology</source><year>2005</year><volume>65</volume><fpage>1941</fpage><lpage>1949</lpage><pub-id pub-id-type="pmid">16380617</pub-id></element-citation></ref><ref id="CIT0016"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michelson</surname><given-names>D</given-names></name><name><surname>Faries</surname><given-names>D</given-names></name><name><surname>Wernicke</surname><given-names>J</given-names></name><name><surname>Kelsey</surname><given-names>D</given-names></name><name><surname>Kendrick</surname><given-names>K</given-names></name><name><surname>Sallee</surname><given-names>FR</given-names></name><name><surname>Spencer</surname><given-names>T.</given-names></name></person-group><article-title>Atomoxetine in the treatment of children and adolescents with attention- deficit/hyperactivity disorder: a randomized, placebo-controlled, dose response study</article-title><source>Pediatrics</source><year>2001</year><volume>108</volume><fpage>83</fpage></element-citation></ref><ref id="CIT0017"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banaschewski</surname><given-names>T</given-names></name><name><surname>Goghill</surname><given-names>D</given-names></name><name><surname>Santosh</surname><given-names>P</given-names></name><name><surname>Zuddes</surname><given-names>A</given-names></name><name><surname>Asherson</surname><given-names>P</given-names></name><name><surname>Buiterlar</surname><given-names>J</given-names></name><name><surname>Danckaerts</surname><given-names>M</given-names></name><name><surname>D&#x000f6;pfner</surname><given-names>M</given-names></name><name><surname>Faraone</surname><given-names>SV</given-names></name><name><surname>Rothenberger</surname><given-names>A</given-names></name><name><surname>Sergeant</surname><given-names>J</given-names></name><name><surname>Steinhausen</surname><given-names>HC</given-names></name><name><surname>Sonuga-Barke</surname><given-names>EJ</given-names></name><name><surname>Taylor</surname><given-names>E.</given-names></name></person-group><article-title>Long-acting medications for the hyperkinetic disorders, a systemic review and European treatment guidline</article-title><source>Eur child Adolesc Psychiatry</source><year>2006</year><volume>15</volume><fpage>476</fpage><lpage>495</lpage><pub-id pub-id-type="pmid">16680409</pub-id></element-citation></ref><ref id="CIT0018"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burns</surname><given-names>MJ.</given-names></name></person-group><article-title>The Pharmacology and Toxicology of Reboxetine</article-title><source>Int J Med Toxicol</source><year>2000</year><volume>3</volume><fpage>26</fpage></element-citation></ref><ref id="CIT0019"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toren</surname><given-names>P</given-names></name><name><surname>Ratner</surname><given-names>S</given-names></name><name><surname>Laor</surname><given-names>N</given-names></name><name><surname>Lerer&#x02013;Amisar</surname><given-names>D</given-names></name><name><surname>Weizman</surname><given-names>A.</given-names></name></person-group><article-title>A possible antienuretic effect of reboxetine in children and adolescents with attention deficit/hyperactivity disorder: Case series</article-title><source>Neuropsychology</source><year>2005</year><volume>51</volume><fpage>239</fpage><lpage>42</lpage></element-citation></ref><ref id="CIT0020"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toren</surname><given-names>P</given-names></name><name><surname>Ratner</surname><given-names>S</given-names></name><name><surname>Weizmen</surname><given-names>A</given-names></name><name><surname>Lask</surname><given-names>M</given-names></name><name><surname>Ben&#x02013;Amitary</surname><given-names>G</given-names></name><name><surname>Laor</surname><given-names>N.</given-names></name></person-group><article-title>Reboxetine maintenance treatment in children with attention deficit hyperactivity disorder: a longterm follow-up study</article-title><source>J child Adolesc Psychopharmacol</source><year>2007</year><volume>17</volume><fpage>803</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">18315452</pub-id></element-citation></ref><ref id="CIT0021"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riahi</surname><given-names>F</given-names></name><name><surname>Tehrani-Doost</surname><given-names>M</given-names></name><name><surname>Shahrivar</surname><given-names>Z</given-names></name><name><surname>Alaghband-Rad</surname><given-names>J.</given-names></name></person-group><article-title>Efficacy of reboxetine in adults with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled clinical trial</article-title><source>Hum Psychopharmacol Clin Exp</source><year>2010</year><volume>25</volume><fpage>570</fpage><lpage>576</lpage></element-citation></ref><ref id="CIT0022"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hale</surname><given-names>AS</given-names></name><name><surname>Pinninti</surname><given-names>NR.</given-names></name></person-group><article-title>Critical flicker fusion threshold and anticholinergic effects of chronic antidepressant treatment in remitted depressives</article-title><source>J psychopharmacol</source><year>1995</year><volume>9</volume><fpage>258</fpage><lpage>266</lpage><pub-id pub-id-type="pmid">22297766</pub-id></element-citation></ref><ref id="CIT0023"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hindmarch</surname><given-names>I.</given-names></name></person-group><article-title>Reboxetine and Psychomotor Function</article-title><source>Eur Neuropsychopharmacol</source><year>1997</year><volume>7</volume><fpage>17</fpage><lpage>21</lpage></element-citation></ref><ref id="CIT0024"><label>24</label><element-citation publication-type="book"><collab>American Psychiatric Association</collab><article-title>Diagnostic and Statistical Manual of Mental Disorders</article-title><source>4th ed</source><publisher-loc>Washington, DC</publisher-loc><publisher-name>American Psychiatric Association</publisher-name><comment>Text Revision</comment></element-citation></ref><ref id="CIT0025"><label>25</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Mc Gough</surname><given-names>JJ</given-names></name></person-group><person-group person-group-type="editor"><name><surname>BJ</surname><given-names>Sadock</given-names></name><name><surname>VA</surname><given-names>sadock</given-names></name></person-group><article-title>Adult manifestations of attention-deficit/hyperactivity disorder</article-title><source>Comprehensive textbook of Psychiatry</source><year>2005</year><publisher-name>Philadelphia:Lippincott Williams and Wilkins</publisher-name><fpage>3198</fpage><lpage>3208</lpage><comment>8th ed</comment></element-citation></ref><ref id="CIT0026"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tucha</surname><given-names>O</given-names></name><name><surname>Prell</surname><given-names>S</given-names></name><name><surname>Mecklinger</surname><given-names>L</given-names></name><name><surname>Bormann&#x02013;Kischkel</surname><given-names>C</given-names></name><name><surname>Kubber</surname><given-names>S</given-names></name><name><surname>Linder</surname><given-names>M</given-names></name><name><surname>Walitza</surname><given-names>S</given-names></name><name><surname>Lange</surname><given-names>KW.</given-names></name></person-group><article-title>Effects of methylphenidate on multiple componts of attention in children with attention deficit hyperactivity disorder</article-title><source>Psychopharmacology</source><year>2006</year><volume>185</volume><fpage>315</fpage><lpage>326</lpage><pub-id pub-id-type="pmid">16521033</pub-id></element-citation></ref><ref id="CIT0027"><label>27</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>M</given-names></name><name><surname>Weiss</surname><given-names>G</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Lewis</surname><given-names>M</given-names></name></person-group><source>Child and adolescent Psychiatry</source><year>2002</year><publisher-loc>Philadelphia</publisher-loc><publisher-name>Lippincott Williams and Wilkins</publisher-name><fpage>645</fpage><lpage>665</lpage><comment>3th ed</comment></element-citation></ref><ref id="CIT0028"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Safer</surname><given-names>DJ.</given-names></name></person-group><article-title>Central stimulant treatment of childhood attention deficit/hyperactivity disorder across the life cycle</article-title><source>CNS drugs</source><year>1997</year><volume>7</volume><fpage>264</fpage><lpage>272</lpage></element-citation></ref><ref id="CIT0029"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tenreiro</surname><given-names>K.</given-names></name></person-group><article-title>Methylphenidate&#x02013;Placebo: a trial for attention deficit disorders</article-title><source>Int J pharm compd</source><year>2001</year><volume>5</volume><fpage>21</fpage><lpage>22</lpage></element-citation></ref><ref id="CIT0030"><label>30</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Sadock</surname><given-names>BJ</given-names></name><name><surname>Sadock</surname><given-names>VA</given-names></name></person-group><article-title>Synopsis of psychiatry</article-title><source>9<sup>th</sup> ed</source></element-citation></ref><ref id="CIT0031"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biederman</surname><given-names>J</given-names></name><name><surname>Faraonce</surname><given-names>S</given-names></name></person-group><article-title>Attention Deficit/Hyperactivity Disorder: A wordwide concern</article-title><source>J Nerv Ment Dis</source><year>2004</year><volume>192</volume><fpage>453</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">15232314</pub-id></element-citation></ref><ref id="CIT0032"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerr</surname><given-names>JS</given-names></name><name><surname>Powell</surname><given-names>J</given-names></name><name><surname>Hindmarch</surname><given-names>I.</given-names></name></person-group><article-title>The effects of reboxetine and amitriptyline, with and without alcohol on cognitive function and psychomotor performance</article-title><source>Br J Clin Pharmacol</source><year>1996</year><volume>42</volume><fpage>239</fpage><lpage>241</lpage><pub-id pub-id-type="pmid">8864325</pub-id></element-citation></ref><ref id="CIT0033"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chamberlain</surname><given-names>SR</given-names></name><name><surname>Del Campo</surname><given-names>N</given-names></name><name><surname>Dowson</surname><given-names>J</given-names></name><name><surname>Muller</surname><given-names>U</given-names></name><name><surname>Clark</surname><given-names>L</given-names></name><name><surname>Robbins</surname><given-names>TW</given-names></name><name><surname>Sahakian</surname><given-names>BJ.</given-names></name></person-group><article-title>Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder</article-title><source>Biol Psychiatry</source><year>2007</year><volume>62</volume><fpage>977</fpage><lpage>984</lpage><pub-id pub-id-type="pmid">17644072</pub-id></element-citation></ref><ref id="CIT0034"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Healy</surname><given-names>D.</given-names></name></person-group><article-title>Reboxetine: its effects as measured by the social Adaptation Self-evaluation Scale</article-title><source>Acta Psychiatr Scand Suppl</source><year>2000</year><volume>402</volume><fpage>45</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">10901159</pub-id></element-citation></ref><ref id="CIT0035"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okta</surname><given-names>JE</given-names></name><name><surname>Mercadant</surname><given-names>MT</given-names></name><name><surname>Scahill</surname><given-names>L</given-names></name><name><surname>Leckman</surname><given-names>JF.</given-names></name></person-group><article-title>Reboxetine as a potentially effective treatment for attention deficit/hyperactivity disorder (letter to the editor)</article-title><source>J Child Adolesc Psychopharmacol</source><year>2001</year><volume>11</volume><fpage>203</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">11436962</pub-id></element-citation></ref><ref id="CIT0036"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferguson</surname><given-names>J</given-names></name><name><surname>Wesnes</surname><given-names>K</given-names></name><name><surname>Schwartz</surname><given-names>G.</given-names></name></person-group><article-title>Reboxetine Versus Paroxetine Versus Placebo: effects on Cognitive functioning in depressed patients</article-title><source>Int Clin Psychopharmacol</source><year>2003</year><volume>18</volume><fpage>9</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">12490769</pub-id></element-citation></ref><ref id="CIT0037"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hindmarch</surname><given-names>I.</given-names></name></person-group><article-title>Effect of antidepressants on cognitive and psychomotor function: the lack of effect of reboxetine</article-title><source>Human Psycophamacol</source><year>1998</year><volume>13</volume><fpage>S21</fpage><lpage>S27</lpage></element-citation></ref><ref id="CIT0038"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siepmann</surname><given-names>M</given-names></name><name><surname>Muck-Weymann</surname><given-names>M</given-names></name><name><surname>Joraschky</surname><given-names>P</given-names></name><name><surname>Kirch</surname><given-names>W.</given-names></name></person-group><article-title>The effects of reboxetine on autonomic and cognitive functions in healthy volunteers</article-title><source>Psychopharmacology</source><year>2001</year><volume>157</volume><fpage>202</fpage><lpage>207</lpage><pub-id pub-id-type="pmid">11594447</pub-id></element-citation></ref></ref-list></back></article>